O2matic’s Proprietary Technology to be Evaluated by the University of Colorado, Funded by the U.S. Department of Defense
Dr. Ginde and his team’s work has paved the way for the SAVE-O2 trial, a multicenter randomized clinical trial funded by the U.S. Department of Defense.
- Dr. Ginde and his team’s work has paved the way for the SAVE-O2 trial, a multicenter randomized clinical trial funded by the U.S. Department of Defense.
- The SAVE-O2 trial focuses on redefining oxygen requirements in critically ill trauma patients through targeting normoxemia.
- Their advancements in oxygen therapy protocols have already begun to influence guidelines, with updates to 10 relevant Joint Trauma System guidelines.
- Dr. Ginde and his team are now evaluating the efficacy of automatic oxygen therapy technology, with O2matic’s proprietary technology chosen for a multi-center study involving 300 patients.